The new vanguard of domestic regenerative medicine, Ascension medical biotechnology Co., Ltd., at its own international market strategy conference on January 10, disclosed the market and unique technology of the company’s first marketed exosome based product “ExoGioV “seize the global ten billions of beauty market.
The Ministry of Health and Welfare, Taiwan announced in No. 1081601760 in 2019 “List of Prohibited Ingredients in Cosmetics” that stipulates that human-derived cells, tissues and their products are not allowed to be added to cosmetics. AM biotech enters the international market with ExoGiov, a cosmetic ingredient that complies with Taiwan and international cosmetic regulations. AM biotech is the first company in Taiwan to use exosome derived from non-human cells and obtain the international cosmetic ingrdient certification INCI, which complies with the international regulations for beauty care products and can be used in medical beauty, beauty SPA, personal skin care products. ExoGiov is totally different with the other exosome based products in the worldwide due that its uniqueness on product and technology . In 2022, it had successfully attracted the attention in the international market especially on Europe, Italy, Japan, ASEAN countries and China which have been on the stage of business negotiation.
The global medical beauty market and personal beauty care products have been growing continuously in recent years. According to Statista analysis, the personal care beauty care product market revenue will reach 528.6 billion US dollars in 2022. The market is projected to grow by 4.64% annually (CAGR 2022-2027). IMARC Group also predicts that the global medical beauty market will reach US$13.9 billion in 2021, and US$24.53 billion by 2027, with a compound annual growth rate of 9.60% between 2022 and 2027, which shows that the beauty-related industry is the industry that has grown steadily against the trend in the post-epidemic era. AM biotech intends to catch up with this development trend, take advantage of the trend, and pave the way for the company’s future regenerative medicine and new drug research and development.
According to Dr. Richard Shieh’s statement, ExoGiov is the selected exosome and specific for skin care, beauty and hair growth which produced by their self-developed bio-pulsed patent technology, next-generation gene sequencing (NGS) and quantitative polymerase chain reaction (QPCR) .
The features of ExoGiov which are also the international market focus are as below:
(1) Non-human chicken embryonic mesenchymal stem cells obtained from the laboratory and without special disease source (SPF), and obtained the international cosmetic ingredient certification INCI, completely legal and compliant.
(2) The IRB human cell efficacy study cooperatively conducted by The National Defense Medical College,Taiwan. The study result was jointly published in the International Journal of Molecular Sciences, an international academic journal.
(3) The efficacy can reach dozens of times that of ordinary exosomes. Such as, the proliferation rate of collagen and elastin can be more than 300%, the proliferation rate of fibroblast can be more than 50%, and the proliferation rate of hair follicle cells can be more than 120%.
(4)With the exclusive extraction and lyophilization technology of AM Biotech, the purity of exosome can reach 99.99%, and whether it is liquid or lyophilization powder form, it can be used and stored at room temperature.
AM Biotech also plan to organize the “Seminar on the Application of Exosomes in Beauty, Skin Care and Hair Growth” in early March together with domestic academic research institutes and beauty-related societies, hoping that more domestic medical and beauty practitioners will have an in-depth understanding the various applications of Exosome ,the future stars of the beauty industry. It will bring brand-new “beauty and revitalization” to users.
